Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis
| Autor: | Andreas Hermes, Benjamin Waschki, Ulrich Gatzemeier, Martin Reck |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Pathology Lung Neoplasms LDH Survival Gastroenterology Small-cell carcinoma chemistry.chemical_compound Internal medicine Lactate dehydrogenase medicine Carcinoma Humans Clinical significance Stage (cooking) Carcinoma Small Cell Aged Neoplasm Staging Retrospective Studies Aged 80 and over Prognostic factor Lung Small cell lung cancer L-Lactate Dehydrogenase business.industry Cancer Retrospective cohort study Middle Aged medicine.disease Prognosis medicine.anatomical_structure chemistry Female business Biomarkers |
| Zdroj: | Respiratory medicine. 104(12) |
| ISSN: | 1532-3064 |
| Popis: | SummaryPurposeThe aim of this retrospective study is to present data on clinical significance of lactate dehydrogenase (LDH) serum levels in an unselected contemporary patient population with small cell lung cancer (SCLC) in limited disease (LD) and extensive disease stage (ED).Patients and methodsFrom June 2004 to June 2008, our electronic database including all in-patient and out-patient contacts was searched for patients with newly diagnosed LD and ED SCLC. 397 cases were identified. We collected data on patient characteristics including clinical performance status and LDH serum levels, metastatic sites, efficacy of first line chemotherapy and survival.ResultsIn both limited and extensive disease SCLC, elevated LDH serum levels resulted in significantly shorter median survival. The effect was most pronounced if levels were 300 U/l or higher. In patients with limited disease and normal LDH levels, median survival was 18.0 months. If LDH was higher than 300 U/l, overall survival was reduced to 12 months. In cases with extensive disease, overall survival was significantly lower in patients with elevated LDH serum levels with an additional reduction in overall survival in patients with LDH levels above 300 U/l. (7.0 vs. 12.0 months, p = |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect